TNSN05298A1 - Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases - Google Patents

Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases

Info

Publication number
TNSN05298A1
TNSN05298A1 TNP2005000298A TNSN05298A TNSN05298A1 TN SN05298 A1 TNSN05298 A1 TN SN05298A1 TN P2005000298 A TNP2005000298 A TN P2005000298A TN SN05298 A TNSN05298 A TN SN05298A TN SN05298 A1 TNSN05298 A1 TN SN05298A1
Authority
TN
Tunisia
Prior art keywords
pyrazolo
preparation
quinazoline derivatives
kinase inhibitors
deregulation
Prior art date
Application number
TNP2005000298A
Other languages
English (en)
Inventor
Gabriella Traquandi
Maria Gabriella Brasca
Roberto D'alessio
Paolo Polucci
Fulvia Roletto
Anna Vulpetti
Paolo Pevarello
Achille Panzeri
Francesca Quartieri
Ron Ferguson
Paola Vianello
Daniele Fancelli
Original Assignee
Nerviano Medical Sciences S R I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN05298(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences S R I filed Critical Nerviano Medical Sciences S R I
Publication of TNSN05298A1 publication Critical patent/TNSN05298A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Des dérivés de pyrazolo-quinazoline de formule (Ia) ou (Ib), répondant à la définition figurant dans le présent mémoire, et leurs sels pharmaceutiquement acceptables, un procédé pour leur préparation et des compositions pharmaceutiques les comprenant sont décrits ; Les composés de la présente invention peuvent être utiles, en thérapeutique, dans le traitement de maladies associées à une dérégulation d'activité de protéine-kinase, telles que le cancer.
TNP2005000298A 2003-05-22 2005-11-21 Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases TNSN05298A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22
PCT/EP2004/050612 WO2004104007A1 (fr) 2003-05-22 2004-04-27 Derives de pyrazolo-quinazoline, procede de preparation associe et leur utilisation en tant qu'inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
TNSN05298A1 true TNSN05298A1 (fr) 2007-07-10

Family

ID=33476970

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000298A TNSN05298A1 (fr) 2003-05-22 2005-11-21 Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases

Country Status (36)

Country Link
US (8) US7482354B2 (fr)
EP (1) EP1636236B1 (fr)
JP (1) JP5043432B2 (fr)
KR (1) KR101084871B1 (fr)
CN (2) CN102079746A (fr)
AP (1) AP2064A (fr)
AR (2) AR044543A1 (fr)
AU (1) AU2004240772B2 (fr)
BR (2) BR122019010200B8 (fr)
CA (1) CA2526578C (fr)
CO (1) CO5721006A2 (fr)
CR (1) CR8102A (fr)
CY (1) CY1114708T1 (fr)
DK (1) DK1636236T3 (fr)
EA (1) EA010904B1 (fr)
EC (1) ECSP056194A (fr)
ES (1) ES2436524T3 (fr)
GE (1) GEP20094664B (fr)
HR (1) HRP20050967B8 (fr)
IL (1) IL172046A (fr)
IS (1) IS2939B (fr)
ME (1) ME00142B (fr)
MX (1) MXPA05012573A (fr)
MY (1) MY142019A (fr)
NO (1) NO334992B1 (fr)
NZ (1) NZ543661A (fr)
OA (1) OA13170A (fr)
PL (1) PL1636236T3 (fr)
PT (1) PT1636236E (fr)
RS (2) RS20050944A (fr)
SI (1) SI1636236T1 (fr)
TN (1) TNSN05298A1 (fr)
TW (1) TWI349672B (fr)
UA (1) UA80763C2 (fr)
WO (1) WO2004104007A1 (fr)
ZA (1) ZA200509486B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526578C (fr) * 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Derives de pyrazolo-quinazoline, procede de preparation associe et leur utilisation en tant qu'inhibiteurs de kinase
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007090794A1 (fr) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinaisons comprenant un inhibiteur de cdk et un anticorps anti-facteur de croissance ou un antimitotique
CN101443002B (zh) * 2006-05-09 2012-03-21 诺瓦提斯公司 包含铁螯合剂和抗肿瘤药的组合及其用途
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
CN101563351B (zh) * 2006-12-21 2013-06-05 内尔维阿诺医学科学有限公司 取代的吡唑并-喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
DK2125822T3 (en) * 2006-12-21 2015-01-12 Nerviano Medical Sciences Srl SUBSTITUTED PYRAZOLOQUINAZOLINDERIVATER, process for their preparation and their use as kinase inhibitors
AU2008315048A1 (en) 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
EP2278973B1 (fr) * 2008-04-07 2011-11-02 Amgen Inc. Amino-pyridines/pyrimidines spirocycliques et gem-disubstituées en tant qu'inhibiteurs du cycle cellulaire
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
EA020703B9 (ru) * 2008-06-26 2015-12-30 Ле Лаборатуар Сервье Пиразолохиназолины
ES2622559T3 (es) * 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
CN102105151B (zh) * 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
US8653097B2 (en) * 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
EP2376084B1 (fr) * 2008-11-24 2013-07-17 Nerviano Medical Sciences S.r.l. Inhibiteur de CDK pour le traitement d'un mésothéliome
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CN102356083B (zh) * 2009-03-20 2014-10-15 内尔维阿诺医学科学有限公司 用于胸腺瘤治疗的激酶抑制剂的用途
US9243000B2 (en) 2009-04-22 2016-01-26 Boehringer Ingelheim International Gmbh Thia-triaza-indacenes
WO2010125004A1 (fr) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Sels d'inhibiteurs de cdk
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
CN103626777B (zh) * 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
AU2011210765A1 (en) * 2010-01-28 2012-09-13 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
JP5997143B2 (ja) * 2010-07-30 2016-09-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
WO2012038521A1 (fr) 2010-09-23 2012-03-29 Syngenta Participations Ag Microbiocides inédits
SI2632467T1 (sl) * 2010-10-25 2016-10-28 G1 Therapeutics, Inc. Inhibitorji CDK
EP2614065B1 (fr) * 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Dérivés de pyrazolo-quinazoline substitués à titre d'inhibiteurs de kinases
CN103339134B (zh) * 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
US8916577B2 (en) * 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
WO2012117021A2 (fr) 2011-03-03 2012-09-07 Syngenta Participations Ag Nouveaux éthers d'oxime microbiocides
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
CN103635230B (zh) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
WO2013092460A1 (fr) 2011-12-20 2013-06-27 Syngenta Participations Ag Microbicides bisoximes cycliques
WO2013110585A1 (fr) * 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines en tant qu'inhibiteurs d'igf-lr/lr
EP2641901A1 (fr) 2012-03-22 2013-09-25 Syngenta Participations AG. Nouveaux microbicides bisoximes
CN108047219A (zh) 2012-11-07 2018-05-18 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
WO2014116228A1 (fr) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Inhibiteurs de l'usp14 utilisables en vue du traitement ou de la prévention d'infections virales
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
WO2015073528A1 (fr) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Composés renforçant l'activité des protéasomes
US9856258B2 (en) 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
WO2015161283A1 (fr) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques à utiliser dans des traitements de la prolifération de cellules anormales rb-positives, épargnant les cellules souches et les cellules progénitrices hématopoïétiques (hspc)
EP3148532B1 (fr) 2014-05-28 2021-03-03 Piramal Enterprises Limited Association pharmaceutique comprenant un inhibiteur de cdk et un inhibiteur de thiorédoxine réductase pour le traitement du cancer
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
CN108348486A (zh) 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
JP2019524723A (ja) 2016-07-15 2019-09-05 アンスティテュ・パストゥール 皮膚および／または毛の修復のための５−ヒドロキシトリプタミン１ｂ受容体刺激剤
DK3505519T3 (da) * 2016-11-11 2022-02-07 Yangtze River Pharm Group Co Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin
JP7178401B2 (ja) * 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
WO2021043190A1 (fr) * 2019-09-05 2021-03-11 成都赛诺希亚生物科技有限公司 Composés isoxazolo[5,4-h]quinazoline utilisés en tant qu'inhibiteurs de protéine kinase
WO2021084541A1 (fr) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Traitement de troubles du type perte de cheveux avec un inhibiteur topique d'egfr
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (fr) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 Composé pyrazoloquinazoline, son procédé de préparation et son utilisation
JP2024505714A (ja) * 2021-02-08 2024-02-07 メッドシャイン ディスカバリー インコーポレイテッド ５，６－ジドヒロチエノ［３，４－ｈ］キナゾリン系化合物
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
WO2023104178A1 (fr) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 Inhibiteur de protéine kinase, son procédé de préparation et son application

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
WO1996040142A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
CA2416527C (fr) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles actifs en tant qu'inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les contenant
MXPA03001306A (es) * 2000-08-11 2003-10-15 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina.
CA2430151A1 (fr) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Derives phenylacetamido-pyrazole et leur utilisation comme agents antitumoraux
EP1379524A2 (fr) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2456939A1 (fr) * 2001-08-10 2003-02-20 Pharmacia Corporation Inhibiteur d'anhydrase carbonique
EA007430B1 (ru) 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
AU2003225580A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
CA2526578C (fr) * 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Derives de pyrazolo-quinazoline, procede de preparation associe et leur utilisation en tant qu'inhibiteurs de kinase
DK2125822T3 (en) * 2006-12-21 2015-01-12 Nerviano Medical Sciences Srl SUBSTITUTED PYRAZOLOQUINAZOLINDERIVATER, process for their preparation and their use as kinase inhibitors

Also Published As

Publication number Publication date
PL1636236T3 (pl) 2014-02-28
MY142019A (en) 2010-08-16
CN1826343A (zh) 2006-08-30
TW200505924A (en) 2005-02-16
MEP25908A (en) 2010-06-10
US20130338148A1 (en) 2013-12-19
NO20055496L (no) 2006-02-14
BRPI0410563B1 (pt) 2020-12-01
AR102722A2 (es) 2017-03-22
AP2064A (en) 2009-10-30
EA010904B1 (ru) 2008-12-30
AR044543A1 (es) 2005-09-21
US9637497B2 (en) 2017-05-02
RS20050944A (en) 2008-06-05
EP1636236B1 (fr) 2013-10-09
HRP20050967B8 (hr) 2014-04-25
US8541429B2 (en) 2013-09-24
UA80763C2 (en) 2007-10-25
BR122019010200B1 (pt) 2020-12-15
DK1636236T3 (da) 2013-12-09
ZA200509486B (en) 2008-09-25
WO2004104007A1 (fr) 2004-12-02
PT1636236E (pt) 2013-12-16
IS2939B (is) 2016-03-15
HRP20050967A2 (en) 2007-05-31
NO20055496D0 (no) 2005-11-21
US20070185143A1 (en) 2007-08-09
BR122019010200B8 (pt) 2021-07-27
JP5043432B2 (ja) 2012-10-10
MXPA05012573A (es) 2006-02-22
OA13170A (en) 2006-12-13
US8981089B2 (en) 2015-03-17
US20090124605A1 (en) 2009-05-14
KR20060015294A (ko) 2006-02-16
CR8102A (es) 2006-08-09
TWI349672B (en) 2011-10-01
GEP20094664B (en) 2009-04-10
ES2436524T3 (es) 2014-01-02
NO334992B1 (no) 2014-08-18
IL172046A (en) 2017-03-30
US9464090B2 (en) 2016-10-11
US20210300935A1 (en) 2021-09-30
JP2007502851A (ja) 2007-02-15
AU2004240772A1 (en) 2004-12-02
US20170190714A1 (en) 2017-07-06
NZ543661A (en) 2009-05-31
US20150158876A1 (en) 2015-06-11
KR101084871B1 (ko) 2011-11-21
ME00142B (me) 2010-10-10
CN102079746A (zh) 2011-06-01
CA2526578C (fr) 2012-01-24
HRP20050967B1 (hr) 2014-03-28
CO5721006A2 (es) 2007-01-31
US7482354B2 (en) 2009-01-27
BRPI0410563B8 (pt) 2021-05-25
ECSP056194A (es) 2006-04-19
SI1636236T1 (sl) 2014-01-31
RS52899B (en) 2014-02-28
AP2005003452A0 (en) 2005-12-31
US20170050972A1 (en) 2017-02-23
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
US10280176B2 (en) 2019-05-07
US20190194214A1 (en) 2019-06-27
AU2004240772B2 (en) 2011-04-28
BRPI0410563A (pt) 2006-06-20
CA2526578A1 (fr) 2004-12-02
IS8132A (is) 2005-11-18
EP1636236A1 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA27711A1 (fr) Derives de pyrazolo [1,5-a] pyrimidine
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA32306B1 (fr) Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases
TNSN05250A1 (fr) Pyrimidinones substituees
MA31766B1 (fr) Composés organiques
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
JP2018513868A (ja) キナーゼを阻害する組成物及び方法